Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients

Journal of Medical Virology

Volumn 75, Issue 4, 2005, Pages 528-537

  Vallet, Sophie ^a,b   Gouriou, Stephanie ^b   Nousbaum, Jean Baptiste ^c   Legrand Quillien, Marie Christine ^a   Goudeau, Alain ^d   Picard, Bertrand ^a  

^a CHU MORVAN   (France)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d UNIVERSITÉ DE TOURS   (France)

Author keywords

HCV; NS3 serine protease; Polymorphism; Quasispecies

Indexed keywords

ANTIVIRUS AGENT; NS3 PROTEASE; PEGINTERFERON ALPHA2B; PROTEINASE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CLONE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 1A; HEPATITIS C VIRUS 1B; HUMAN; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION;

AMINO ACID SEQUENCE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS); VIRAL NONSTRUCTURAL PROTEINS;

EID: 13144290646     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20302     Document Type: Article

References (58)

1. Alfonso V, Flichman DM, Sookoian S, Mbayed VA, Campos RH. 2004. Evolutionary study of HVR1 of E2 in chronic hepatitis C virus infection. J Gen Virol 85:39-46.
2. Bartenschlager R. 1999. The NS3/4A proteinase of the hepatitis C virus: Unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Viral Hepat 6:165-181.
3. Bartenschlager R, Lohmann V. 2001. Novel cell culture systems for the hepatitis C virus. Antiviral Res 52:1-17.
4. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. 1994. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol 68:5045-5055.
5. Beyer BM, Zhang R, Hong Z, Madison V, Malcolm BA. 2001. Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity. Proteins 43:82-88.
6. Bianchi E, Pessi A. 2002. Inhibiting viral proteases: Challenges and opportunities. Biopolymers 66:101-114.
7. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ. 1991. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 88:2451-2455.
8. Darling JM, Wright TL. 2004. Immune responses in hepatitis C: Is virus or host the problem? Curr Opin Infect Dis 17:193-198.
9. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. 2003. Approaching a new era for hepatitis C virus therapy: Inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 58:1-16.
10. Domingo E. 1998. Quasispecies and the implications for virus persistence and escape. Clin Diagn Virol 10:97-101.
11. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70:3763-3769.
12. Eckart MR, Selby M, Masiarz F, Lee C, Berger K, Crawford K, Kuo C, Kuo G, Houghton M, Choo QL. 1993. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun 192:399-406.
13. Failla C, Tomei L, De Francesco R. 1995. An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. J Virol 69:1769-1777.
14. Farci P, Purcell RH. 2000. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 20:103-126.
15. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N. 1992. Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135-140.
16. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. 2000. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339-344.
17. Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, Schianchi C, Missale G, Marin MG, Fiaccadori F. 1994. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 19:286-295.
18. Filocamo G, Pacini L, Nardi C, Bartholomew L, Scaturro M, Delmastro P, Tramontano A, De Francesco R, Migliaccio G. 1999. Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric sindbis viruses. J Virol 73:561-575.
19. Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM, Gale M. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300:1145-1148.
20. Gallinari P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkuhler C, De Francesco R. 1998. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 72:6758-6769.
21. Gaudy C, Moreau A, Veillon P, Temoin S, Lunel F, Goudeau A. 2003. Significance of pretreatment analysis of hepatitis C virus genotype lb hypervariable region 1 sequences to predict antiviral outcome. J Clin Microbiol 41:3615-3622.
22. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. 1993. Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites. J Virol 67:2832-2843.
23. Hempel G, Galle PR, Lohr HF. 2001. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha- treated patients with chronic hepatitis C. J Med Virol 64:340-349.
24. Holland-Staley CA, Kovari LC, Golenberg EM, Pobursky KJ, Mayers DL. 2002. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol 147:1385-1406.
25. Houghton M. 1996. Hepatitis C viruses. In: Howley DMKPM, editor. Fields virology, 3rd edition. Philadelphia: Lippincott-Raven. pp 1035-1058.
26. Ingallinella P, Fattori D, Altamura S, Steinkuhler C, Koch U, Cicero D, Bazzo R, Cortese R, Bianchi E, Pessi A. 2002. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry 41:5483-5492.
27. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ. 1998. Multiple sequence alignment with Clustal X. Trends Biochem Sci 23:403-405.
28. Kabsch W, Sander C. 1983. Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22:2577-2637.
29. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355.
30. Kwasigroch JM, Gilis D, Dehouck Y, Rooman M. 2002. PoPMuSiC, rationally designing point mutations in protein structures. Bioinformatics (Oxford, England) 18:1701-1702.
31. Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA. 1999. Hepatitis C virus NS3/4A protease. Antiviral Res 41:67-84.
32. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
33. Lin C, Pragai BM, Grakoui A, Xu J, Rice CM. 1994. Hepatitis C virus NS3 serine proteinase: Trans-cleavage requirements and processing kinetics. J Virol 68:8147-8157.
34. Lodrini S, Bagaglio S, Canducci F, De Mitri MS, Andreone P, Loggi E, Lazzarin A, Clementi M, Morsica G. 2003. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. J Biol Regul Homeost Agents 17:198-204.
35. Malet I, Belnard M, Agut H, Cahour A. 2003. From RNA to quasispecies: A DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. J Virol Methods 109:161-170.
36. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 66:3225-3229.
37. Mullan B, Kenny-Walsh E, Collins JK, Shanahan F, Fanning LJ. 2001. Inferred hepatitis C virus quasispecies diversity is influenced by choice of DNA polymerase in reverse transcriptase-polymerase chain reactions. Anal Biochem 289:137-146.
38. Nei M, Gojobori T. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 3:418-426.
39. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
40. Nicholas KB, Nicholas HB, Jr., Deerfield DW. 1997. GeneDoc: Analysis and visualization of genetic variation. EmbnewNews 4:14.
41. Pawlotsky JM, McHutchison JG. 2004. Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 39:554-567.
42. Pawlotsky JM, Germanidis G, Frainais PO, Bouvier M, Soulier A, Pellerin M, Dhumeaux D. 1999. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 73:6490-6499.
43. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM. 2001. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75:5703-5710.
44. Pizzi E, Tramontano A, Tomei L, La Monica N, Failla C, Sardana M, Wood T, De Francesco R. 1994. Molecular model of the specificity pocket of the hepatitis C virus protease: Implications for substrate recognition. Proc Natl Acad Sci USA 91:888-892.
45. Salemi M, Vandamme AM. 2002. Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J Mol Evol 54:62-70.
46. Sarrazin C, Bruckner M, Herrmann E, Ruster B, Bruch K, Roth WK, Zeuzem S. 2001. Quasispecies heterogeneity of the carboxyterminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 289:150-163.
47. Sayle RA, Milner-White EJ. 1995. RASMOL: Biomolecular graphics for all. Trends Biochem Sci 20:374.
48. Schechter I, Berger A. 1967. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27:157-162.
49. Simmonds P. 1999. Viral heterogeneity of the hepatitis C virus. J Hepatol 1:54-60.
50. Smith RM, Wu GY. 2003. Structure-based design of hepatitis C virus inhibitors. J Viral Hepat 10:405-412.
51. Smith DB, McAllister J, Casino C, Simmonds P. 1997. Virus 'quasispecies': Making a mountain out of a molehill? J Gen Virol 78:1511-1519.
52. Staden R, Beal KF, Bonfield JK. 2000. The Staden package, 1998. Methods Mol Biol 132:115-130.
53. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. 1993. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67:4017-4026.
54. Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, Narjes F, Muraglia E, Paonessa G, Koch U, De_Francesco R, Steinkuhler C, Migliaccio G. 2003. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 77:3669-3679.
55. Xia X, Xie Z. 2001. DAMBE: Software package for data analysis in molecular biology and evolution. J Hered 92:371-373.
56. Yamada K, Mori A, Seki M, Kimura J, Yuasa S, Matsuura Y, Miyamura T. 1998. Critical point mutations for hepatitis C virus NS3 proteinase. Virology 246:104-112.
57. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, De Francesco R, Kuo LC, Chen Z. 1998. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 7:837-847.
58. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 72:3300-3306.